论文部分内容阅读
Dobutaminc(Do)为β受体兴奋剂(显著β_1受体刺激作用,轻度β_2受体作用)系经静脉非洋地黄类正性肌力药物。我们间断用其治疗严重慢性顽固性充血性心力衰竭(CHF),因洋地黄中毒、Ⅲ度房室传导阻滞等不同禁忌证而不能应用洋地黄类药物及其它药物不能控制的慢性CHF取得满意效果.有人报告β受体拟似剂使血清钾下降而增加发生室性心律失常(VR)的危险,尚没见有对血清镁影响的报告。本研究旨在观察Do对CHF者血清镁的影响及与VR的关系。
Dobutaminc (Do) is a β-receptor agonist (a significant β 1 receptor stimulation, a mild β 2 receptor) is a non-digitalis intravenous inotropic drugs. We are satisfied with the treatment of chronic severe intractable congestive heart failure (CHF) intermittently, the inability to use digitalis and other drugs beyond our control due to different contraindications such as digitalis toxicity and third degree atrioventricular block. Effect. It has been reported that β-receptor mimics reduce serum potassium and increase the risk of developing ventricular arrhythmias (VR). No reports of serum magnesium have been reported yet. The purpose of this study was to investigate the effect of Do on serum magnesium in patients with CHF and its relationship with VR.